nodes	percent_of_prediction	percent_of_DWPC	metapath
Carteolol—ADRB2—prostate cancer	0.586	1	CbGaD
Carteolol—CYP2D6—Bicalutamide—prostate cancer	0.0732	0.505	CbGbCtD
Carteolol—CYP2D6—Abiraterone—prostate cancer	0.0606	0.418	CbGbCtD
Carteolol—CYP2D6—Doxorubicin—prostate cancer	0.0112	0.0773	CbGbCtD
Carteolol—Levobunolol—ADRB2—prostate cancer	0.000963	0.153	CrCbGaD
Carteolol—Cerebrovascular accident—Estradiol—prostate cancer	0.000753	0.00383	CcSEcCtD
Carteolol—Lacrimation—Epirubicin—prostate cancer	0.000752	0.00382	CcSEcCtD
Carteolol—Eye irritation—Capecitabine—prostate cancer	0.000743	0.00378	CcSEcCtD
Carteolol—Insomnia—Degarelix—prostate cancer	0.000737	0.00375	CcSEcCtD
Carteolol—Nadolol—ADRB2—prostate cancer	0.00073	0.116	CrCbGaD
Carteolol—Dyspnoea—Degarelix—prostate cancer	0.000726	0.00369	CcSEcCtD
Carteolol—Syncope—Bicalutamide—prostate cancer	0.000723	0.00368	CcSEcCtD
Carteolol—Hypotension—Cabazitaxel—prostate cancer	0.000717	0.00365	CcSEcCtD
Carteolol—Asthenia—Abiraterone—prostate cancer	0.000716	0.00364	CcSEcCtD
Carteolol—Depression—Goserelin—prostate cancer	0.000716	0.00364	CcSEcCtD
Carteolol—Lacrimation increased—Docetaxel—prostate cancer	0.000711	0.00362	CcSEcCtD
Carteolol—Depression—Conjugated Estrogens—prostate cancer	0.000709	0.00361	CcSEcCtD
Carteolol—Loss of consciousness—Bicalutamide—prostate cancer	0.000709	0.00361	CcSEcCtD
Carteolol—Bupranolol—ADRB2—prostate cancer	0.000696	0.111	CrCbGaD
Carteolol—Lacrimation—Doxorubicin—prostate cancer	0.000695	0.00354	CcSEcCtD
Carteolol—Lacrimation increased—Capecitabine—prostate cancer	0.000688	0.0035	CcSEcCtD
Carteolol—Dyspnoea—Cabazitaxel—prostate cancer	0.000684	0.00348	CcSEcCtD
Carteolol—Keratitis—Epirubicin—prostate cancer	0.000681	0.00347	CcSEcCtD
Carteolol—Sinusitis—Goserelin—prostate cancer	0.000673	0.00343	CcSEcCtD
Carteolol—Bopindolol—ADRB2—prostate cancer	0.000668	0.106	CrCbGaD
Carteolol—Respiratory failure—Docetaxel—prostate cancer	0.000667	0.00339	CcSEcCtD
Carteolol—Sinusitis—Conjugated Estrogens—prostate cancer	0.000667	0.00339	CcSEcCtD
Carteolol—Oedema—Bicalutamide—prostate cancer	0.000658	0.00335	CcSEcCtD
Carteolol—Salbutamol—ADRB2—prostate cancer	0.000655	0.104	CrCbGaD
Carteolol—Asthenia—Nilutamide—prostate cancer	0.000654	0.00333	CcSEcCtD
Carteolol—Asthenia—Flutamide—prostate cancer	0.000651	0.00331	CcSEcCtD
Carteolol—Dizziness—Estrone—prostate cancer	0.000649	0.0033	CcSEcCtD
Carteolol—Shock—Bicalutamide—prostate cancer	0.000647	0.00329	CcSEcCtD
Carteolol—Headache—Estramustine—prostate cancer	0.000644	0.00327	CcSEcCtD
Carteolol—Penbutolol—ADRB2—prostate cancer	0.000637	0.101	CrCbGaD
Carteolol—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000631	0.00321	CcSEcCtD
Carteolol—Cardiac failure congestive—Etoposide—prostate cancer	0.000631	0.00321	CcSEcCtD
Carteolol—Keratitis—Doxorubicin—prostate cancer	0.00063	0.00321	CcSEcCtD
Carteolol—Bronchospasm—Estradiol—prostate cancer	0.000628	0.00319	CcSEcCtD
Carteolol—Visual impairment—Conjugated Estrogens—prostate cancer	0.000615	0.00313	CcSEcCtD
Carteolol—Headache—Estrone—prostate cancer	0.000615	0.00313	CcSEcCtD
Carteolol—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.000615	0.00313	CcSEcCtD
Carteolol—Nausea—Estramustine—prostate cancer	0.00061	0.00311	CcSEcCtD
Carteolol—Dizziness—Nilutamide—prostate cancer	0.000603	0.00307	CcSEcCtD
Carteolol—Dizziness—Flutamide—prostate cancer	0.0006	0.00305	CcSEcCtD
Carteolol—Hypersensitivity—Degarelix—prostate cancer	0.0006	0.00305	CcSEcCtD
Carteolol—Insomnia—Bicalutamide—prostate cancer	0.000595	0.00303	CcSEcCtD
Carteolol—Dyspnoea—Bicalutamide—prostate cancer	0.000587	0.00299	CcSEcCtD
Carteolol—Asthenia—Degarelix—prostate cancer	0.000584	0.00297	CcSEcCtD
Carteolol—Nausea—Estrone—prostate cancer	0.000583	0.00297	CcSEcCtD
Carteolol—Arrhythmia—Goserelin—prostate cancer	0.000576	0.00293	CcSEcCtD
Carteolol—Headache—Nilutamide—prostate cancer	0.000571	0.00291	CcSEcCtD
Carteolol—Arrhythmia—Conjugated Estrogens—prostate cancer	0.00057	0.0029	CcSEcCtD
Carteolol—Headache—Flutamide—prostate cancer	0.000569	0.00289	CcSEcCtD
Carteolol—Depression—Estradiol—prostate cancer	0.000567	0.00289	CcSEcCtD
Carteolol—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000566	0.00288	CcSEcCtD
Carteolol—Hypersensitivity—Cabazitaxel—prostate cancer	0.000565	0.00288	CcSEcCtD
Carteolol—Oedema—Ethinyl Estradiol—prostate cancer	0.000556	0.00283	CcSEcCtD
Carteolol—Conjunctivitis—Estradiol—prostate cancer	0.000553	0.00281	CcSEcCtD
Carteolol—Asthenia—Cabazitaxel—prostate cancer	0.00055	0.0028	CcSEcCtD
Carteolol—Dysgeusia—Conjugated Estrogens—prostate cancer	0.000544	0.00277	CcSEcCtD
Carteolol—Nausea—Nilutamide—prostate cancer	0.000541	0.00276	CcSEcCtD
Carteolol—Nausea—Flutamide—prostate cancer	0.000539	0.00274	CcSEcCtD
Carteolol—Dizziness—Degarelix—prostate cancer	0.000538	0.00274	CcSEcCtD
Carteolol—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000537	0.00273	CcSEcCtD
Carteolol—Sinusitis—Estradiol—prostate cancer	0.000534	0.00272	CcSEcCtD
Carteolol—Diabetes mellitus—Capecitabine—prostate cancer	0.000529	0.00269	CcSEcCtD
Carteolol—Vision blurred—Goserelin—prostate cancer	0.000529	0.00269	CcSEcCtD
Carteolol—Cardiac failure congestive—Docetaxel—prostate cancer	0.000524	0.00267	CcSEcCtD
Carteolol—Vision blurred—Conjugated Estrogens—prostate cancer	0.000524	0.00266	CcSEcCtD
Carteolol—Conjunctivitis—Mitoxantrone—prostate cancer	0.000515	0.00262	CcSEcCtD
Carteolol—Headache—Degarelix—prostate cancer	0.00051	0.0026	CcSEcCtD
Carteolol—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000509	0.00259	CcSEcCtD
Carteolol—Dizziness—Cabazitaxel—prostate cancer	0.000507	0.00258	CcSEcCtD
Carteolol—Visual disturbance—Docetaxel—prostate cancer	0.000502	0.00255	CcSEcCtD
Carteolol—Syncope—Conjugated Estrogens—prostate cancer	0.000498	0.00254	CcSEcCtD
Carteolol—Sinusitis—Mitoxantrone—prostate cancer	0.000497	0.00253	CcSEcCtD
Carteolol—Palpitations—Goserelin—prostate cancer	0.000496	0.00252	CcSEcCtD
Carteolol—Visual impairment—Estradiol—prostate cancer	0.000492	0.0025	CcSEcCtD
Carteolol—Palpitations—Conjugated Estrogens—prostate cancer	0.000491	0.0025	CcSEcCtD
Carteolol—Loss of consciousness—Conjugated Estrogens—prostate cancer	0.000488	0.00248	CcSEcCtD
Carteolol—Bronchospasm—Etoposide—prostate cancer	0.000487	0.00248	CcSEcCtD
Carteolol—Hypersensitivity—Bicalutamide—prostate cancer	0.000485	0.00247	CcSEcCtD
Carteolol—Bradycardia—Mitoxantrone—prostate cancer	0.000485	0.00247	CcSEcCtD
Carteolol—Nausea—Degarelix—prostate cancer	0.000484	0.00246	CcSEcCtD
Carteolol—Headache—Cabazitaxel—prostate cancer	0.000481	0.00245	CcSEcCtD
Carteolol—Lacrimation increased—Epirubicin—prostate cancer	0.00048	0.00244	CcSEcCtD
Carteolol—Asthenia—Bicalutamide—prostate cancer	0.000472	0.0024	CcSEcCtD
Carteolol—Diabetes mellitus—Prednisone—prostate cancer	0.000472	0.0024	CcSEcCtD
Carteolol—Cerebrovascular accident—Capecitabine—prostate cancer	0.00047	0.00239	CcSEcCtD
Carteolol—Diplopia—Capecitabine—prostate cancer	0.00046	0.00234	CcSEcCtD
Carteolol—Pindolol—ADRB2—prostate cancer	0.000459	0.0729	CrCbGaD
Carteolol—Oedema—Goserelin—prostate cancer	0.000458	0.00233	CcSEcCtD
Carteolol—Nausea—Cabazitaxel—prostate cancer	0.000456	0.00232	CcSEcCtD
Carteolol—Atrioventricular block—Epirubicin—prostate cancer	0.000456	0.00232	CcSEcCtD
Carteolol—Oedema—Conjugated Estrogens—prostate cancer	0.000453	0.00231	CcSEcCtD
Carteolol—Cardiac failure congestive—Prednisone—prostate cancer	0.000452	0.0023	CcSEcCtD
Carteolol—Shock—Goserelin—prostate cancer	0.00045	0.00229	CcSEcCtD
Carteolol—Shock—Conjugated Estrogens—prostate cancer	0.000446	0.00227	CcSEcCtD
Carteolol—Lacrimation increased—Doxorubicin—prostate cancer	0.000444	0.00226	CcSEcCtD
Carteolol—Dysgeusia—Estradiol—prostate cancer	0.000435	0.00222	CcSEcCtD
Carteolol—Dizziness—Bicalutamide—prostate cancer	0.000435	0.00221	CcSEcCtD
Carteolol—Hypotension—Goserelin—prostate cancer	0.000428	0.00218	CcSEcCtD
Carteolol—Arrhythmia—Mitoxantrone—prostate cancer	0.000425	0.00216	CcSEcCtD
Carteolol—Hypotension—Conjugated Estrogens—prostate cancer	0.000424	0.00216	CcSEcCtD
Carteolol—Atrioventricular block—Doxorubicin—prostate cancer	0.000422	0.00214	CcSEcCtD
Carteolol—Insomnia—Goserelin—prostate cancer	0.000414	0.00211	CcSEcCtD
Carteolol—Headache—Bicalutamide—prostate cancer	0.000412	0.0021	CcSEcCtD
Carteolol—Insomnia—Conjugated Estrogens—prostate cancer	0.00041	0.00209	CcSEcCtD
Carteolol—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00041	0.00209	CcSEcCtD
Carteolol—Dyspnoea—Goserelin—prostate cancer	0.000408	0.00208	CcSEcCtD
Carteolol—Dysgeusia—Mitoxantrone—prostate cancer	0.000406	0.00206	CcSEcCtD
Carteolol—Bronchospasm—Docetaxel—prostate cancer	0.000404	0.00206	CcSEcCtD
Carteolol—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000404	0.00206	CcSEcCtD
Carteolol—Asthenia—Ethinyl Estradiol—prostate cancer	0.000399	0.00203	CcSEcCtD
Carteolol—Syncope—Estradiol—prostate cancer	0.000399	0.00203	CcSEcCtD
Carteolol—Palpitations—Estradiol—prostate cancer	0.000393	0.002	CcSEcCtD
Carteolol—Bronchospasm—Capecitabine—prostate cancer	0.000391	0.00199	CcSEcCtD
Carteolol—Nausea—Bicalutamide—prostate cancer	0.000391	0.00199	CcSEcCtD
Carteolol—Loss of consciousness—Estradiol—prostate cancer	0.000391	0.00199	CcSEcCtD
Carteolol—Vision blurred—Mitoxantrone—prostate cancer	0.00039	0.00199	CcSEcCtD
Carteolol—Diabetes mellitus—Epirubicin—prostate cancer	0.000369	0.00188	CcSEcCtD
Carteolol—Dizziness—Ethinyl Estradiol—prostate cancer	0.000368	0.00187	CcSEcCtD
Carteolol—Oedema—Estradiol—prostate cancer	0.000363	0.00185	CcSEcCtD
Carteolol—Salbutamol—CYP3A4—prostate cancer	0.000358	0.0569	CrCbGaD
Carteolol—Shock—Estradiol—prostate cancer	0.000357	0.00182	CcSEcCtD
Carteolol—Conjunctivitis—Docetaxel—prostate cancer	0.000356	0.00181	CcSEcCtD
Carteolol—Depression—Capecitabine—prostate cancer	0.000354	0.0018	CcSEcCtD
Carteolol—Cardiac failure congestive—Epirubicin—prostate cancer	0.000354	0.0018	CcSEcCtD
Carteolol—Headache—Ethinyl Estradiol—prostate cancer	0.000348	0.00177	CcSEcCtD
Carteolol—Conjunctivitis—Capecitabine—prostate cancer	0.000345	0.00176	CcSEcCtD
Carteolol—Diabetes mellitus—Doxorubicin—prostate cancer	0.000341	0.00174	CcSEcCtD
Carteolol—Oedema—Mitoxantrone—prostate cancer	0.000338	0.00172	CcSEcCtD
Carteolol—Dysgeusia—Etoposide—prostate cancer	0.000337	0.00172	CcSEcCtD
Carteolol—Hypersensitivity—Goserelin—prostate cancer	0.000337	0.00172	CcSEcCtD
Carteolol—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000334	0.0017	CcSEcCtD
Carteolol—Shock—Mitoxantrone—prostate cancer	0.000333	0.00169	CcSEcCtD
Carteolol—Nausea—Ethinyl Estradiol—prostate cancer	0.00033	0.00168	CcSEcCtD
Carteolol—Hypoglycaemia—Epirubicin—prostate cancer	0.000329	0.00167	CcSEcCtD
Carteolol—Asthenia—Goserelin—prostate cancer	0.000328	0.00167	CcSEcCtD
Carteolol—Insomnia—Estradiol—prostate cancer	0.000328	0.00167	CcSEcCtD
Carteolol—Cerebrovascular accident—Epirubicin—prostate cancer	0.000327	0.00167	CcSEcCtD
Carteolol—Cardiac failure congestive—Doxorubicin—prostate cancer	0.000327	0.00167	CcSEcCtD
Carteolol—Asthenia—Conjugated Estrogens—prostate cancer	0.000325	0.00166	CcSEcCtD
Carteolol—Bradycardia—Capecitabine—prostate cancer	0.000324	0.00165	CcSEcCtD
Carteolol—Dyspnoea—Estradiol—prostate cancer	0.000324	0.00165	CcSEcCtD
Carteolol—Diplopia—Epirubicin—prostate cancer	0.000321	0.00163	CcSEcCtD
Carteolol—Visual impairment—Docetaxel—prostate cancer	0.000317	0.00161	CcSEcCtD
Carteolol—Propranolol—CYP3A5—prostate cancer	0.000317	0.0503	CrCbGaD
Carteolol—Hypotension—Mitoxantrone—prostate cancer	0.000316	0.00161	CcSEcCtD
Carteolol—Depression—Prednisone—prostate cancer	0.000315	0.0016	CcSEcCtD
Carteolol—Visual impairment—Capecitabine—prostate cancer	0.000307	0.00156	CcSEcCtD
Carteolol—Hypoglycaemia—Doxorubicin—prostate cancer	0.000304	0.00155	CcSEcCtD
Carteolol—Loss of consciousness—Etoposide—prostate cancer	0.000303	0.00154	CcSEcCtD
Carteolol—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000303	0.00154	CcSEcCtD
Carteolol—Dizziness—Goserelin—prostate cancer	0.000303	0.00154	CcSEcCtD
Carteolol—Dyspnoea—Mitoxantrone—prostate cancer	0.000301	0.00153	CcSEcCtD
Carteolol—Dizziness—Conjugated Estrogens—prostate cancer	0.0003	0.00153	CcSEcCtD
Carteolol—Diplopia—Doxorubicin—prostate cancer	0.000297	0.00151	CcSEcCtD
Carteolol—Arrhythmia—Docetaxel—prostate cancer	0.000294	0.0015	CcSEcCtD
Carteolol—Bradycardia—Prednisone—prostate cancer	0.000289	0.00147	CcSEcCtD
Carteolol—Headache—Goserelin—prostate cancer	0.000287	0.00146	CcSEcCtD
Carteolol—Arrhythmia—Capecitabine—prostate cancer	0.000285	0.00145	CcSEcCtD
Carteolol—Headache—Conjugated Estrogens—prostate cancer	0.000284	0.00145	CcSEcCtD
Carteolol—Dysgeusia—Docetaxel—prostate cancer	0.00028	0.00143	CcSEcCtD
Carteolol—Nausea—Goserelin—prostate cancer	0.000272	0.00138	CcSEcCtD
Carteolol—Dysgeusia—Capecitabine—prostate cancer	0.000272	0.00138	CcSEcCtD
Carteolol—Nausea—Conjugated Estrogens—prostate cancer	0.000269	0.00137	CcSEcCtD
Carteolol—Hypersensitivity—Estradiol—prostate cancer	0.000267	0.00136	CcSEcCtD
Carteolol—Hypotension—Etoposide—prostate cancer	0.000263	0.00134	CcSEcCtD
Carteolol—Vision blurred—Capecitabine—prostate cancer	0.000261	0.00133	CcSEcCtD
Carteolol—Asthenia—Estradiol—prostate cancer	0.00026	0.00132	CcSEcCtD
Carteolol—Syncope—Docetaxel—prostate cancer	0.000257	0.00131	CcSEcCtD
Carteolol—Arrhythmia—Prednisone—prostate cancer	0.000253	0.00129	CcSEcCtD
Carteolol—Palpitations—Docetaxel—prostate cancer	0.000253	0.00129	CcSEcCtD
Carteolol—Loss of consciousness—Docetaxel—prostate cancer	0.000252	0.00128	CcSEcCtD
Carteolol—Dyspnoea—Etoposide—prostate cancer	0.000251	0.00128	CcSEcCtD
Carteolol—Propranolol—ADRB2—prostate cancer	0.00025	0.0398	CrCbGaD
Carteolol—Hypersensitivity—Mitoxantrone—prostate cancer	0.000249	0.00127	CcSEcCtD
Carteolol—Syncope—Capecitabine—prostate cancer	0.000249	0.00127	CcSEcCtD
Carteolol—Palpitations—Capecitabine—prostate cancer	0.000245	0.00125	CcSEcCtD
Carteolol—Loss of consciousness—Capecitabine—prostate cancer	0.000244	0.00124	CcSEcCtD
Carteolol—Asthenia—Mitoxantrone—prostate cancer	0.000243	0.00123	CcSEcCtD
Carteolol—Conjunctivitis—Epirubicin—prostate cancer	0.00024	0.00122	CcSEcCtD
Carteolol—Dizziness—Estradiol—prostate cancer	0.00024	0.00122	CcSEcCtD
Carteolol—Oedema—Docetaxel—prostate cancer	0.000234	0.00119	CcSEcCtD
Carteolol—Vision blurred—Prednisone—prostate cancer	0.000233	0.00118	CcSEcCtD
Carteolol—Sinusitis—Epirubicin—prostate cancer	0.000232	0.00118	CcSEcCtD
Carteolol—Shock—Docetaxel—prostate cancer	0.00023	0.00117	CcSEcCtD
Carteolol—Headache—Estradiol—prostate cancer	0.000227	0.00116	CcSEcCtD
Carteolol—Oedema—Capecitabine—prostate cancer	0.000226	0.00115	CcSEcCtD
Carteolol—Bradycardia—Epirubicin—prostate cancer	0.000226	0.00115	CcSEcCtD
Carteolol—Shock—Capecitabine—prostate cancer	0.000223	0.00113	CcSEcCtD
Carteolol—Conjunctivitis—Doxorubicin—prostate cancer	0.000222	0.00113	CcSEcCtD
Carteolol—Syncope—Prednisone—prostate cancer	0.000222	0.00113	CcSEcCtD
Carteolol—Hypotension—Docetaxel—prostate cancer	0.000218	0.00111	CcSEcCtD
Carteolol—Loss of consciousness—Prednisone—prostate cancer	0.000217	0.0011	CcSEcCtD
Carteolol—Propranolol—CYP2C19—prostate cancer	0.000216	0.0342	CrCbGaD
Carteolol—Nausea—Estradiol—prostate cancer	0.000216	0.0011	CcSEcCtD
Carteolol—Propranolol—CYP1A1—prostate cancer	0.000215	0.0341	CrCbGaD
Carteolol—Sinusitis—Doxorubicin—prostate cancer	0.000215	0.00109	CcSEcCtD
Carteolol—Visual impairment—Epirubicin—prostate cancer	0.000214	0.00109	CcSEcCtD
Carteolol—Headache—Mitoxantrone—prostate cancer	0.000212	0.00108	CcSEcCtD
Carteolol—Hypotension—Capecitabine—prostate cancer	0.000211	0.00108	CcSEcCtD
Carteolol—Insomnia—Docetaxel—prostate cancer	0.000211	0.00108	CcSEcCtD
Carteolol—Bradycardia—Doxorubicin—prostate cancer	0.000209	0.00106	CcSEcCtD
Carteolol—Dyspnoea—Docetaxel—prostate cancer	0.000208	0.00106	CcSEcCtD
Carteolol—Hypersensitivity—Etoposide—prostate cancer	0.000207	0.00105	CcSEcCtD
Carteolol—Insomnia—Capecitabine—prostate cancer	0.000205	0.00104	CcSEcCtD
Carteolol—Asthenia—Etoposide—prostate cancer	0.000202	0.00103	CcSEcCtD
Carteolol—Dyspnoea—Capecitabine—prostate cancer	0.000202	0.00103	CcSEcCtD
Carteolol—Oedema—Prednisone—prostate cancer	0.000202	0.00103	CcSEcCtD
Carteolol—Nausea—Mitoxantrone—prostate cancer	0.000201	0.00102	CcSEcCtD
Carteolol—Shock—Prednisone—prostate cancer	0.000198	0.00101	CcSEcCtD
Carteolol—Arrhythmia—Epirubicin—prostate cancer	0.000198	0.00101	CcSEcCtD
Carteolol—Visual impairment—Doxorubicin—prostate cancer	0.000198	0.00101	CcSEcCtD
Carteolol—Dysgeusia—Epirubicin—prostate cancer	0.000189	0.000963	CcSEcCtD
Carteolol—Dizziness—Etoposide—prostate cancer	0.000186	0.000946	CcSEcCtD
Carteolol—Arrhythmia—Doxorubicin—prostate cancer	0.000183	0.000933	CcSEcCtD
Carteolol—Insomnia—Prednisone—prostate cancer	0.000182	0.000928	CcSEcCtD
Carteolol—Vision blurred—Epirubicin—prostate cancer	0.000182	0.000926	CcSEcCtD
Carteolol—Headache—Etoposide—prostate cancer	0.000176	0.000897	CcSEcCtD
Carteolol—Dysgeusia—Doxorubicin—prostate cancer	0.000175	0.000891	CcSEcCtD
Carteolol—Syncope—Epirubicin—prostate cancer	0.000173	0.000881	CcSEcCtD
Carteolol—Hypersensitivity—Docetaxel—prostate cancer	0.000172	0.000876	CcSEcCtD
Carteolol—Palpitations—Epirubicin—prostate cancer	0.000171	0.000869	CcSEcCtD
Carteolol—Loss of consciousness—Epirubicin—prostate cancer	0.00017	0.000864	CcSEcCtD
Carteolol—Vision blurred—Doxorubicin—prostate cancer	0.000168	0.000857	CcSEcCtD
Carteolol—Asthenia—Docetaxel—prostate cancer	0.000168	0.000853	CcSEcCtD
Carteolol—Nausea—Etoposide—prostate cancer	0.000167	0.00085	CcSEcCtD
Carteolol—Hypersensitivity—Capecitabine—prostate cancer	0.000167	0.000848	CcSEcCtD
Carteolol—Asthenia—Capecitabine—prostate cancer	0.000162	0.000826	CcSEcCtD
Carteolol—Syncope—Doxorubicin—prostate cancer	0.00016	0.000816	CcSEcCtD
Carteolol—Palpitations—Doxorubicin—prostate cancer	0.000158	0.000804	CcSEcCtD
Carteolol—Oedema—Epirubicin—prostate cancer	0.000158	0.000802	CcSEcCtD
Carteolol—Loss of consciousness—Doxorubicin—prostate cancer	0.000157	0.000799	CcSEcCtD
Carteolol—Shock—Epirubicin—prostate cancer	0.000155	0.000789	CcSEcCtD
Carteolol—Dizziness—Docetaxel—prostate cancer	0.000155	0.000786	CcSEcCtD
Carteolol—Dizziness—Capecitabine—prostate cancer	0.00015	0.000761	CcSEcCtD
Carteolol—Hypersensitivity—Prednisone—prostate cancer	0.000149	0.000756	CcSEcCtD
Carteolol—Hypotension—Epirubicin—prostate cancer	0.000147	0.00075	CcSEcCtD
Carteolol—Headache—Docetaxel—prostate cancer	0.000146	0.000745	CcSEcCtD
Carteolol—Oedema—Doxorubicin—prostate cancer	0.000146	0.000742	CcSEcCtD
Carteolol—Asthenia—Prednisone—prostate cancer	0.000145	0.000736	CcSEcCtD
Carteolol—Shock—Doxorubicin—prostate cancer	0.000144	0.00073	CcSEcCtD
Carteolol—Insomnia—Epirubicin—prostate cancer	0.000143	0.000726	CcSEcCtD
Carteolol—Headache—Capecitabine—prostate cancer	0.000142	0.000721	CcSEcCtD
Carteolol—Dyspnoea—Epirubicin—prostate cancer	0.000141	0.000715	CcSEcCtD
Carteolol—Nausea—Docetaxel—prostate cancer	0.000139	0.000706	CcSEcCtD
Carteolol—Propranolol—CYP3A4—prostate cancer	0.000137	0.0218	CrCbGaD
Carteolol—Hypotension—Doxorubicin—prostate cancer	0.000136	0.000694	CcSEcCtD
Carteolol—Nausea—Capecitabine—prostate cancer	0.000134	0.000684	CcSEcCtD
Carteolol—Dizziness—Prednisone—prostate cancer	0.000133	0.000678	CcSEcCtD
Carteolol—Insomnia—Doxorubicin—prostate cancer	0.000132	0.000671	CcSEcCtD
Carteolol—Dyspnoea—Doxorubicin—prostate cancer	0.00013	0.000662	CcSEcCtD
Carteolol—Headache—Prednisone—prostate cancer	0.000126	0.000643	CcSEcCtD
Carteolol—Nausea—Prednisone—prostate cancer	0.00012	0.000609	CcSEcCtD
Carteolol—Hypersensitivity—Epirubicin—prostate cancer	0.000116	0.000591	CcSEcCtD
Carteolol—Asthenia—Epirubicin—prostate cancer	0.000113	0.000576	CcSEcCtD
Carteolol—Hypersensitivity—Doxorubicin—prostate cancer	0.000107	0.000547	CcSEcCtD
Carteolol—Asthenia—Doxorubicin—prostate cancer	0.000105	0.000533	CcSEcCtD
Carteolol—Dizziness—Epirubicin—prostate cancer	0.000104	0.00053	CcSEcCtD
Carteolol—Headache—Epirubicin—prostate cancer	9.88e-05	0.000503	CcSEcCtD
Carteolol—Dizziness—Doxorubicin—prostate cancer	9.65e-05	0.000491	CcSEcCtD
Carteolol—Nausea—Epirubicin—prostate cancer	9.37e-05	0.000477	CcSEcCtD
Carteolol—Headache—Doxorubicin—prostate cancer	9.14e-05	0.000465	CcSEcCtD
Carteolol—Nausea—Doxorubicin—prostate cancer	8.67e-05	0.000441	CcSEcCtD
Carteolol—ADRB1—Signaling Pathways—PRKACB—prostate cancer	2.17e-05	0.000328	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PTHLH—prostate cancer	2.17e-05	0.000328	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—TGFBR1—prostate cancer	2.17e-05	0.000328	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—ARG2—prostate cancer	2.17e-05	0.000328	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PHGDH—prostate cancer	2.17e-05	0.000328	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—UMPS—prostate cancer	2.17e-05	0.000328	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—AKR1C3—prostate cancer	2.13e-05	0.000322	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—LDHB—prostate cancer	2.12e-05	0.000321	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PRKACB—prostate cancer	2.12e-05	0.000321	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PPP3CA—prostate cancer	2.11e-05	0.00032	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—THBS1—prostate cancer	2.11e-05	0.00032	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP3A5—prostate cancer	2.09e-05	0.000315	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—ANXA1—prostate cancer	2.08e-05	0.000315	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PPP3CA—prostate cancer	2.07e-05	0.000313	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—THBS1—prostate cancer	2.07e-05	0.000313	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PRKCZ—prostate cancer	2.04e-05	0.000309	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—ANXA1—prostate cancer	2.04e-05	0.000308	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PDHA1—prostate cancer	2.01e-05	0.000305	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—UCP3—prostate cancer	2.01e-05	0.000305	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTA3—prostate cancer	2.01e-05	0.000305	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—TCN2—prostate cancer	2.01e-05	0.000305	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PRKCZ—prostate cancer	2e-05	0.000303	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—PIK3CG—prostate cancer	2e-05	0.000302	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—FGFR4—prostate cancer	1.97e-05	0.000299	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PARP1—prostate cancer	1.97e-05	0.000299	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—PIK3CG—prostate cancer	1.95e-05	0.000296	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CALCA—prostate cancer	1.95e-05	0.000295	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PARP1—prostate cancer	1.93e-05	0.000292	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—FGFR4—prostate cancer	1.93e-05	0.000292	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—HSD3B1—prostate cancer	1.92e-05	0.000291	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—SLC22A3—prostate cancer	1.92e-05	0.000291	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CALCA—prostate cancer	1.91e-05	0.000289	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CXCL12—prostate cancer	1.9e-05	0.000288	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CXCL12—prostate cancer	1.86e-05	0.000282	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTA4—prostate cancer	1.84e-05	0.000279	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—TBXAS1—prostate cancer	1.84e-05	0.000279	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—PIK3CG—prostate cancer	1.81e-05	0.000274	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTA2—prostate cancer	1.79e-05	0.000272	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CASP9—prostate cancer	1.79e-05	0.000271	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—PIK3CG—prostate cancer	1.77e-05	0.000269	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—ABCG5—prostate cancer	1.77e-05	0.000268	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—SULT1A1—prostate cancer	1.77e-05	0.000268	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	1.76e-05	0.000266	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CASP9—prostate cancer	1.75e-05	0.000265	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	1.74e-05	0.000263	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—NGFR—prostate cancer	1.74e-05	0.000263	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTA1—prostate cancer	1.73e-05	0.000262	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	1.72e-05	0.00026	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	1.72e-05	0.00026	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTO1—prostate cancer	1.71e-05	0.000259	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—HSD3B2—prostate cancer	1.71e-05	0.000259	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—NAT2—prostate cancer	1.71e-05	0.000259	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	1.7e-05	0.000257	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—NGFR—prostate cancer	1.7e-05	0.000257	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	1.68e-05	0.000254	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—FGF10—prostate cancer	1.65e-05	0.00025	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PLCB2—prostate cancer	1.64e-05	0.000248	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—LRP2—prostate cancer	1.64e-05	0.000248	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP2C18—prostate cancer	1.64e-05	0.000248	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	1.63e-05	0.000247	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—FGF10—prostate cancer	1.62e-05	0.000244	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	1.61e-05	0.000244	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—P4HB—prostate cancer	1.61e-05	0.000244	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	1.61e-05	0.000243	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	1.6e-05	0.000241	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—VAV3—prostate cancer	1.59e-05	0.000241	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	1.58e-05	0.000239	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	1.57e-05	0.000238	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	1.57e-05	0.000238	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—SLC22A1—prostate cancer	1.57e-05	0.000237	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	1.56e-05	0.000236	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	1.56e-05	0.000236	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	1.55e-05	0.000234	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	1.54e-05	0.000232	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	1.53e-05	0.000232	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—SULT2A1—prostate cancer	1.53e-05	0.000231	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	1.51e-05	0.000229	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—MED12—prostate cancer	1.5e-05	0.000227	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	1.5e-05	0.000227	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GNG5—prostate cancer	1.49e-05	0.000225	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	1.48e-05	0.000224	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	1.47e-05	0.000223	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	1.46e-05	0.000221	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	1.45e-05	0.000219	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	1.44e-05	0.000218	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—NCOA3—prostate cancer	1.43e-05	0.000217	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	1.43e-05	0.000217	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—LPL—prostate cancer	1.42e-05	0.000214	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	1.41e-05	0.000213	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	1.4e-05	0.000212	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	1.39e-05	0.00021	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—LPL—prostate cancer	1.39e-05	0.00021	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	1.38e-05	0.000208	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	1.37e-05	0.000208	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—HPGDS—prostate cancer	1.37e-05	0.000207	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	1.37e-05	0.000207	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP2C19—prostate cancer	1.36e-05	0.000206	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	1.36e-05	0.000206	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	1.34e-05	0.000203	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	1.34e-05	0.000202	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—ACHE—prostate cancer	1.33e-05	0.000201	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTT1—prostate cancer	1.33e-05	0.000201	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	1.33e-05	0.000201	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	1.33e-05	0.0002	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP2A6—prostate cancer	1.31e-05	0.000199	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	1.31e-05	0.000198	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	1.3e-05	0.000196	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	1.3e-05	0.000196	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	1.28e-05	0.000193	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—AKR1C3—prostate cancer	1.28e-05	0.000193	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—TERT—prostate cancer	1.27e-05	0.000192	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PRKACB—prostate cancer	1.27e-05	0.000192	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP17A1—prostate cancer	1.26e-05	0.00019	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	1.25e-05	0.000189	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—TERT—prostate cancer	1.24e-05	0.000188	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	1.22e-05	0.000184	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—NCOA2—prostate cancer	1.2e-05	0.000181	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	1.19e-05	0.00018	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—LEP—prostate cancer	1.19e-05	0.00018	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	1.18e-05	0.000178	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—KDR—prostate cancer	1.16e-05	0.000176	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—LEP—prostate cancer	1.16e-05	0.000176	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	1.15e-05	0.000174	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.14e-05	0.000173	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—KDR—prostate cancer	1.14e-05	0.000172	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	1.13e-05	0.000172	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.12e-05	0.000169	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	1.11e-05	0.000168	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—BAD—prostate cancer	1.11e-05	0.000167	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—NQO1—prostate cancer	1.1e-05	0.000167	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—TH—prostate cancer	1.09e-05	0.000165	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—BAD—prostate cancer	1.08e-05	0.000164	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.08e-05	0.000163	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	1.07e-05	0.000162	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—APC—prostate cancer	1.07e-05	0.000162	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	1.06e-05	0.00016	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—EGF—prostate cancer	1.06e-05	0.00016	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.06e-05	0.00016	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—APC—prostate cancer	1.05e-05	0.000159	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	1.05e-05	0.000159	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—EGF—prostate cancer	1.04e-05	0.000157	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	1.04e-05	0.000157	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	1.03e-05	0.000156	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GGT1—prostate cancer	1.02e-05	0.000155	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—INS—prostate cancer	1.01e-05	0.000153	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—NCOA1—prostate cancer	1.01e-05	0.000153	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	1.01e-05	0.000152	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP19A1—prostate cancer	9.95e-06	0.00015	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	9.94e-06	0.00015	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—INS—prostate cancer	9.93e-06	0.00015	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	9.81e-06	0.000148	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	9.77e-06	0.000148	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	9.72e-06	0.000147	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	9.6e-06	0.000145	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—RXRA—prostate cancer	9.6e-06	0.000145	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	9.55e-06	0.000145	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	9.49e-06	0.000143	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	9.42e-06	0.000143	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	9.33e-06	0.000141	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	9.32e-06	0.000141	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	9.28e-06	0.00014	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—COMT—prostate cancer	9.25e-06	0.00014	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	9.23e-06	0.00014	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	9.22e-06	0.000139	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTP1—prostate cancer	9.2e-06	0.000139	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	9.13e-06	0.000138	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	9.12e-06	0.000138	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—ITPR1—prostate cancer	9.06e-06	0.000137	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	9.02e-06	0.000137	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	9.02e-06	0.000136	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	8.9e-06	0.000135	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	8.83e-06	0.000134	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	8.7e-06	0.000132	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	8.65e-06	0.000131	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—TYMS—prostate cancer	8.56e-06	0.000129	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	8.48e-06	0.000128	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	8.46e-06	0.000128	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—GSTM1—prostate cancer	8.46e-06	0.000128	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	8.44e-06	0.000128	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	8.32e-06	0.000126	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—LPL—prostate cancer	8.3e-06	0.000126	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	8.29e-06	0.000125	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	8.26e-06	0.000125	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	8.21e-06	0.000124	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	8.14e-06	0.000123	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	8.03e-06	0.000122	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CYP1A1—prostate cancer	8.02e-06	0.000121	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—ERCC2—prostate cancer	7.95e-06	0.00012	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	7.89e-06	0.000119	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	7.72e-06	0.000117	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	7.71e-06	0.000117	CbGpPWpGaD
Carteolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	7.62e-06	0.000115	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	7.55e-06	0.000114	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—IL2—prostate cancer	7.54e-06	0.000114	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	7.54e-06	0.000114	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	7.5e-06	0.000114	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—MTHFR—prostate cancer	7.47e-06	0.000113	CbGpPWpGaD
Carteolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	7.46e-06	0.000113	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	7.39e-06	0.000112	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—IL2—prostate cancer	7.38e-06	0.000112	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	7.35e-06	0.000111	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	7.34e-06	0.000111	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PPARA—prostate cancer	7.33e-06	0.000111	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	7.28e-06	0.00011	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	7.19e-06	0.000109	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	7.14e-06	0.000108	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	7.12e-06	0.000108	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	7.11e-06	0.000108	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	7.1e-06	0.000107	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	6.98e-06	0.000106	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	6.96e-06	0.000105	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	6.94e-06	0.000105	CbGpPWpGaD
Carteolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	6.92e-06	0.000105	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CAV1—prostate cancer	6.89e-06	0.000104	CbGpPWpGaD
Carteolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	6.77e-06	0.000102	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—EP300—prostate cancer	6.77e-06	0.000102	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—EP300—prostate cancer	6.62e-06	0.0001	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—SRC—prostate cancer	6.58e-06	9.96e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—SRC—prostate cancer	6.44e-06	9.74e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	6.41e-06	9.7e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	6.35e-06	9.6e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PIK3CG—prostate cancer	6.28e-06	9.5e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	6.27e-06	9.49e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	6.21e-06	9.39e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—INS—prostate cancer	5.94e-06	8.99e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—MYC—prostate cancer	5.9e-06	8.92e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	5.88e-06	8.9e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—CREBBP—prostate cancer	5.82e-06	8.81e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—MYC—prostate cancer	5.77e-06	8.73e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	5.77e-06	8.73e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	5.76e-06	8.71e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	5.64e-06	8.54e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PIK3CD—prostate cancer	5.52e-06	8.35e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	5.45e-06	8.24e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	5.33e-06	8.06e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—NOS3—prostate cancer	5.21e-06	7.89e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	5.01e-06	7.57e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	4.9e-06	7.41e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—TP53—prostate cancer	4.84e-06	7.33e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PIK3CB—prostate cancer	4.81e-06	7.28e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PTGS2—prostate cancer	4.77e-06	7.21e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—TP53—prostate cancer	4.74e-06	7.17e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—IL6—prostate cancer	4.43e-06	6.71e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—IL6—prostate cancer	4.34e-06	6.56e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PTEN—prostate cancer	4.16e-06	6.29e-05	CbGpPWpGaD
Carteolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	4.09e-06	6.19e-05	CbGpPWpGaD
Carteolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	4e-06	6.05e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—EP300—prostate cancer	3.97e-06	6e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.93e-06	4.44e-05	CbGpPWpGaD
Carteolol—CYP2D6—Metabolism—AKT1—prostate cancer	2.4e-06	3.63e-05	CbGpPWpGaD
